Katya Meridor

Dr. Katya Meridor

Department of Internal Medicine, Meir Medical Center, Kfar Saba, Israel
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2021 in Medicine
Verified
Journal Article
Open access
KMKatya Meridor
Katya Meridor
YSYehuda Shoenfeld
Yehuda Shoenfeld
Oshrat E. Tayer-ShifmanOshrat E. Tayer-Shifman
Oshrat E. Tayer-Shifman
YLYair Levy
Yair Levy
Introduction: Intravenous immunoglobulin (IVIg) is currently used with considerable success for the treatment of many autoimmune diseases, including systemic lupus erythematosus (SLE). Among its various indications, IVIg has also been found to be beneficial in myocarditis, whether or not it is associated with an autoimmune disease. Nevertheless, data regarding IVIg treatment for myocarditis/cardiomyopathy in patients with SLE are sparse. The objective of this case series was to describe our experience with IVIg as a treatment for lupus myocarditis and to review the literature for IVIg for this indication. Patient concerns: We report 5 female patients with SLE, who presented with signs of acute heart failure including pulmonary congestion and arrhythmias. Diagnosis: Echocardiography demonstrated new reduced left ventricular ejection fraction of 20% to 30%. Two patients underwent coronary artery angiography, which demonstrated normal coronary arteries, supporting the diagnosis of myocarditis or nonischemic cardiomyopathy. Interventions: High-dose IVIg treatment was initiated in all 5 patients. Outcomes: Following the treatment, clinical and echocardiographic improvement in cardiac function occurred within a few days to 1 month. This dramatic improvement persisted for several years. Conclusion: Based on our case series, we believe that IVIg has an important role in the management of lupus acute cardiomyopathy. This safe, well-tolerated optional treatment should be considered, especially in severe cases.

17 May 2014 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
JHJigal Haas
Jigal Haas
Yoav YinonYoav Yinon
Yoav Yinon
KMKatya Meridor
Katya Meridor
Raoul OrvietoRaoul Orvieto
Raoul Orvieto
Various inflammatory cytokines have been implicated in the pathophysiology of severe ovarian hyperstimulation syndrome, as well as, various pregnancy complications, including preterm labor, pregnancy induced hypertension/preeclampsia and intra-uterine growth restriction. We aim to determine whether severe OHSS, complicated by third space fluid accumulation necessitating drainage, is associated with increased risk of late obstetrics complications.

28 January 2022 in Medicine
Verified
Journal Article
Open access
KMKatya Meridor
Katya Meridor
JBJoshua Berookhim
Joshua Berookhim
LYLevy. Yair
Levy. Yair
Rationale: Pruritus is a common symptom in patients with systemic sclerosis and has a tremendous effect on the quality of life. Nevertheless, current therapeutic options are limited. The pathogenesis of pruritus in systemic sclerosis is not completely understood; however, opiate-mediated neurotransmission has been postulated to be involved. Patient concerns and diagnosis: We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D-itch score of 22.75. Intervention and outcomes: Low-dose oral naloxone was initiated, followed by a significant improvement in the level of pruritus, reaching an average 5D-itch score of 7.5, after 6 and 12 months of treatment. None of the patients experienced side effects. Lessons: Low-dose naloxone plays an important role in the management of pruritus in systemic sclerosis.

2 December 2025 in Rheumatology
Verified
Journal Article
Open access
KMKatya Meridor
Katya Meridor
SHStephanie R Harrison
Stephanie R Harrison
RPRichard Parker
Richard Parker
CCChenchu Chimakurthi
Chenchu Chimakurthi
PLPhilip M Laws
Philip M Laws
JFJane E Freeston
Jane E Freeston
Objectives: To evaluate the performance of non-invasive screening tools in identifying metabolic dysfunction-associated steatotic liver disease (MASLD) causing clinically significant liver disease (CSLD) in PsA patients at high risk for liver disease, and to identify factors associated with CSLD. Methods: A single-centre, cross-sectional study of PsA patients referred for liver assessment due to suspected CSLD secondary to MASLD was conducted. Fibrosis-4 (FIB-4), Enhanced Liver Fibrosis (ELF) and BARD (BMI, aspartate aminotransferase/alanine transaminase ratio and Diabetes) scores were calculated using routine laboratory and clinical data. Liver imaging was performed as clinically indicated, including FibroScan in most patients. CSLD was defined as liver stiffness measurement (LSM) >10 kPa on FibroScan and/or US and/or biopsy showing steatosis/fibrosis/cirrhosis secondary to MASLD. Univariable and multivariable analyses identified variables independently associated with CSLD. Results: Eighty-nine PsA patients were included (median age 51.0 years; 57.3% male). Cardiometabolic comorbidities were common: 96.6% had one or more metabolic risk factor and 69.7% were obese. CSLD was identified in 55/89 patients (61.8%). In univariable analyses, hypertriglyceridaemia, hypertension, statin use, BMI >30 kg/m2, higher ELF and FIB-4 scores, and elevated LSM were significantly associated with CSLD. In multivariable regression, hypertension, BMI >30 kg/m2 and FIB-4 ≥1.3 remained independently associated. FIB-4 ≥1.3 demonstrated sensitivity of 47.8%, specificity of 77.2%, positive predictive value of 6.1% and negative predictive value of 98.0%. MTX exposure was not associated with CSLD. Conclusions: CSLD is common in high-risk PsA patients and strongly associated with metabolic risk factors. FIB-4 ≥1.3 had high negative predictive value, supporting its use as a first-line screening tool. Routine MASLD screening using a pathway incorporating FIB-4 followed by FibroScan may inform safer prescribing and improve outcomes.

12 June 2026 in Current Rheumatology Reports
Verified
Journal Article
Open access
EDEmilio D’IGnazio
Emilio D’IGnazio
DSDidem Sahin
Didem Sahin
Caterina BaldiCaterina Baldi
Caterina Baldi
PEPaul Emery
Paul Emery
DMDennis McGonagle
Dennis McGonagle
AMAndrea Di Matteo
Andrea Di Matteo
Purpose of Review: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with highly heterogeneous clinical manifestations associated with psoriasis (PsO). The wide variability in presentation, together with the absence of definitive serological biomarkers, makes early diagnosis particularly challenging. This review evaluates the role of ultrasound in identifying and characterising musculoskeletal involvement across the psoriatic disease (PsD) continuum—from asymptomatic PsO to established PsA. Recent Findings: Ultrasound can detect subclinical synovitis, enthesitis, peritendonitis, tenosynovitis, bursitis, and structural damage in PsD. Evidence highlights its value in the early identification of musculoskeletal changes in patients with PsO who are at risk of progressing to PsA, with important implications for disease interception and prevention. Additional applications include differential diagnosis; assessment of enthesitis and distinction between inflammatory and non-inflammatory disease; and monitoring of therapeutic response, including in refractory disease. Ultrasound also demonstrates prognostic utility by detecting subclinical inflammation, predicting flares and future structural damage, and supporting personalized treatment strategies. Standardized ultrasound scoring systems and emerging methods for evaluating small hand entheses and dactylitis are also discussed. Summary: Ultrasound is an important tool for early detection, prognostic assessment, and management guidance in PsA, offering potential to prevent disease progression and inform precision medicine approach.

19 May 2025 in Rheumatology
Verified
Journal Article
Closed access
KMKatya Meridor
Katya Meridor
VFVictoria Furer
Victoria Furer
TSTzipora Shochat
Tzipora Shochat
OEOfir Elalouf
Ofir Elalouf
OEOri Elkayam
Ori Elkayam
APAri Polachek
Ari Polachek
Objectives: To evaluate the discordance between patients’ global assessments (PGA) and evaluators’ global assessments (EGA) in psoriatic arthritis (PsA), and to explore the association of clinical variables, patient-reported outcomes (PROs) and ultrasound (US) factors with this discordance. Methods: Consecutive PsA patients (CASPAR criteria) were prospectively recruited and evaluated by a comprehensive clinical examination, PROs and sonographic assessment (including 52 joints, 40 tendons and 14 entheses). EGA was scored by rheumatologists blinded to the PGA. Discordance between PGA and EGA was considered significant if the delta was ≥3. The US assessor was blinded to the clinical data. The concordant and discordant groups were compared, and factors associated with discordance were evaluated through a multivariate regression analysis. Results: Of the 158 PsA patients who were included, 88 (55.7%) patients were considered discordant, with the mean difference between PGA and EGA of 3.3. The discordant group had significantly higher tender joint counts (TJC), enthesitis, C-reactive protein (CRP) and lower working status rates compared with the concordant group (P < 0.05). US scores were similar between the groups. Patients with discordance had significantly higher PsA activity scores, a higher prevalence of fibromyalgia and worse PROs, including pain, depression, fatigue and measures of quality of life (P < 0.05). On multivariate regression, higher TJC, lower swollen joint counts and depression were associated with greater discordance (OR 1.07, OR 0.85 and OR 1.05, respectively, P < 0.05). Conclusion: The discrepancy between PGA and EGA in PsA is characterized by worse disease activity scores and worse subjective measures but not by sonographic measures.